The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Italy

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Phase 2 · randomised · 120 people · 33 sites in 6 countries · Recruiting now

August 7, 2026
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers

Phase 2 · 220 people · 55 sites in 13 countries · Recruiting now

August 7, 2026
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Phase 2 · randomised · 1,109 people · 47 sites in 8 countries · Recruiting now

August 7, 2026
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Phase 2 · randomised · 108 people · 59 sites in 15 countries · Running, not taking new patients

August 7, 2026
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer

Phase 1 · randomised · 542 people · 84 sites in 11 countries · Recruiting now

August 7, 2026
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 2 · randomised · 768 people · 105 sites in 10 countries · Recruiting now

August 7, 2026
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 2 · 560 people · 54 sites in 7 countries · Recruiting now

August 7, 2026
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Phase 2 · 140 people · 48 sites in 8 countries · Recruiting now

August 7, 2026
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Phase 2 · randomised · 80 people · 76 sites in 12 countries · Recruiting now

August 7, 2026
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

Phase 2 · randomised · 302 people · 109 sites in 22 countries · Running, not taking new patients

August 7, 2026